Angiogenesis is regulated by the balance between angiogenic stimulators and inhibitors. Numerous reports have demonstrated that tumors induce aggressive angiogenesis by upregulating the production of angiogenesis stimulating growth factors to overcome the baseline levels of endogenous inhibitors. However, the possibility of large differences in the host's responsiveness to angiogenic factors has been largely overlooked. Using the corneal micropocket neovascularization assay, we have observed >10-fold differences in responsiveness to either basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) among various mouse strains. The inheritance pattern observed for these traits supported a QTL (quantitative trait locus) approach to mapping the genes responsible for the differences in angiogenic responsiveness. To overcome variability in the assay, we used recombinant inbred lines to map this phenotype. In the BXD series of recombinant inbred mouse strains, we have mapped the regions responsible for regulating VEGF-induced angiogenesis using both composite interval mapping and multiple interval mapping. Both approaches link VEGF responsiveness to regions on chromosomes 2 (near D2Mit6) and 10 (near D10Mit20). Candidate angiogenesisrelated genes in these regions include those for collagen XVIII/endostatin, matrix metalloproteinase 11, integrin β 2 , prostaglandin D2 synthase, and interleukin-1 receptor antagonist.
angiogenic responsiveness among various strains has been observed in additional species and anatomical locations with both bFGF and vascular endothelial growth factor (VEGF) (5, 6) .
VEGF was initially identified as vascular permeability factor and later as a vascular endothelial specific growth factor (7, 8) . VEGF has been shown to be overexpressed in the tumor and/or stromal component of most tumors as well as in some premalignant lesions (9) . VEGF signaling occurs when the protein binds to one of its receptors (Flt-1, KDR/Flk-1), initiating a signaling cascade that includes activation of PLC-gamma, PI3-kinase, MAP kinase, and rapid Ca 2+ influx. This induces endothelial cell changes that result in increased vascular permeability, cell migration, cell division, and activation of the clotting and later the fibrinolytic pathways, with subsequent tissue remodeling (9) . In addition, VEGF acts as an antiapoptotic survival factor and induces expression of angiopoietin 2, thereby inhibiting vessel maturation (10) . VEGF may also indirectly stimulate angiogenesis via activation of macrophages/monocyte chemotaxis (11) . Alterations in the genes responsible for any of these activities may have significant effects on VEGF-induced angiogenesis.
To explore those genetic factors responsible for differential responsiveness to VEGF, we chose an interval mapping strategy to identify QTLs (quantitative trait loci) and, eventually, genes responsible for differential VEGF effects in mice. Interval mapping (12) considers the probability that a QTL is positioned between two markers and allows the position and effect of a QTL to be distinguished. However, simple interval mapping (SIM) assumes that the phenotype results from a single linked QTL, resulting in artificially low significance of association. SIM may be inadequate for systems in which multiple contributing loci are expected based on the phenotype distribution (13) . Composite interval mapping (CIM) reduces these limitations by accounting for the effect of previously modeled QTLs while searching for additional ones (14, 15) . It allows only independent effects to be easily modeled and is therefore likely to miss epistatic interactions. Multiple interval mapping (MIM) (16) uses multiple regression techniques to detect not only QTLs with independent effects, but also those with effects that are only significant as pairwise epistatic effects. MIM can detect QTLs with increased power and precision when compared with other methods. The newness of this technique, however, complicates analysis because appropriate methods for significance testing of predicted QTLs are currently uncertain (16) . To maximize the likelihood of detecting QTLs responsible for VEGFinduced angiogenesis, we have used both a CIM approach and a MIM approach in these experiments.
MATERIALS AND METHODS

Mouse strains and corneal micropocket assay
The corneal micropocket assay was performed as previously described (17) using pellets containing 80 ng of bFGF or 180 ng carrier free human recombinant VEGF 165 (R&D Systems, Minneapolis, MN) in C57BL/6J mice. The area of vascular response was assessed on the fifth (bFGF) or sixth (VEGF) postoperative day, using a slit lamp. Attempts were made to make comparable measurements by holding mice until several strains could be assayed at once, thus reducing lot-to-lot variability in the pellets and reducing pellet age differences. This resulted in mice of several different ages (52-223 days, mean 83.4 ±31.2 SD) being assayed; however, in cases where the same strain was assayed at different ages, a significant difference in results was not observed. Indeed, an assay comparing 2-month-old C57BL/6J mice to >1-year-old mice of the same strain showed no significant difference. Five mice (10 eyes) per BXD strain were analyzed, and similar numbers of control C57BL/6J and DBA/2J were included in each assay to confirm consistency. In the case of the BXD-2 strain, anomalous results (the pellet disappeared) prevented our acquiring reliable data, and this strain was excluded from further analysis. All mouse strains were obtained from Jackson Laboratories (Bar Harbor, ME) and were housed in Children's Hospital's animal facility on standard diet and bedding until the assay was performed. All animal studies were conducted according to protocols approved by the Institutional Animal Care and Use Committee of Children's Hospital.
Multiple linear regression was performed on right eye vessel area using the formula A = α + β 1 a + β 2 e + β 3 x + β 4 g + ε, where a is the deviation of the animals age from the mean animal age, e is the deviation of left vessel area from the strain and experiment mean, x is the deviation of the C57BL/6J mean in that experiment from the C57BL/6J mean in all experiments, and g is the deviation of the strain mean from the B6D2F1/J mean. Regression was also explored using the following model: A = (α + β 1 a + β 2 e + β 4 g) (C + β 3 x) + ε (where C is the C57BL/6J strain mean value) under the hypothesis that differences in C57BL/6J control values resulted from differences in VEGF availability in different pellet batches (response to growth factor amount in this assay is generally linear in this range), but important differences in the results of the two models was not observed. Significance in regression was determined using an F test.
QTL analysis software
Windows QTL Cartographer version 1.3 (18) was used throughout for linkage analysis. Default settings were used throughout unless otherwise noted. Significance levels for interval mapping were determined by permutation using 10,000 iterations. Likelihood ratio (LR) scores for various P values are as follows: P < 0.05 = 17.8, P < 0.01 = 22.1, P < 0.001 = 26.4. CIM was performed using both forward regression with 5 and 6 control markers (default) and forward regression with backward elimination to select control markers. No appreciable difference was observed in the data resulting from the two methods of control marker selection. MIM was performed using CIM to select an initial model, with software defaults used otherwise.
Genotyping and mapping
Genotypes for BXD strains and linkage map data were obtained from the Mouse Genome Database version 2.8, Nov. 8, 2002 (MGD, http://www.jax.org) (19) . This database was also used to identify additional markers polymorphic between C57BL/6J and DBA/2J mice. Genotyping of BXD strains was performed by PCR using primers annotated in the MGD and DNA purchased from Jackson Laboratories or purified directly from the animals assayed. Cycling profiles were determined empirically and performed in a PTC-200 thermal cycler (MJ Research, Reno, Nevada). Taq polymerase and other PCR reagents were from Qiagen (Valencia, California). These data have been deposited in the MGD.
Physical map positions were obtained where possible from the UCSC annotation of the mouse genome (Feb. 2002 assembly of the mouse genome at http://genome.cse.ucsc.edu/). Where a marker had no UCSC annotated position on the MGSCv3 assembly, the NCBI annotated position (http://www.ncbi.nlm.nih.gov/mapview/static/MVstart.html) was used. No attempt was made to correct positions in the NCBI assembly because <2% of our marker positions annotated in both assemblies differ by >250 bp. For linkage analysis, data was converted to a pseudocentimorgan scale by dividing the position of the marker in Mbp by 2.
RESULTS
Previous studies have shown a substantial difference in angiogenic responsiveness to bFGF among various inbred mouse strains (4) . To confirm that this variability extends to VEGF responsiveness, we performed the corneal neovascularization assay on 12 different inbred mouse strains, using VEGF to stimulate vessel growth. As with bFGF, we observed dramatic variations in responsiveness to an angiogenic stimulus among various mouse strains ( Fig. 1) , with the vessel area in response to a 180 ng VEGF pellet ranging from 0.4 to 2.2 mm 2 . We also observed that VEGF responsiveness correlated generally, but not perfectly, to bFGF responsiveness ( Fig.  1) , with ~60% of the variance in the mean strain bFGF responsiveness explicable by mean strain VEGF responsiveness (P<0.005 for the correlation by F test). This is consistent with the observation that about half of the bFGF response in the corneal neovascularization assay can be blocked by VEGF antagonists and therefore relies on the VEGF pathway (R. D'Amato, manuscript in preparation). Others have also reported that VEGF is secondarily induced by bFGF (20) .
To map QTLs associated with VEGF responsiveness, we used recombinant inbred (RI) strains. We chose to map angiogenic responsiveness genes using a RI strain set derived from the C57BL/6J strain because its angiogenic responsiveness sits at the mode of the strains tested ( Fig.  1 ) and because its genome is being sequenced by the public genome project (21) . Thus, C57BL/6J provides a good baseline for both genetic mapping and for analysis of sequence variation. Because the BXD series is the largest set of RIs derived from the C57BL/6J mouse strain, we performed the corneal neovascularization assay on all that were commercially available ( Table 1) .
Phenotyping of F1 progeny of C57BL/6J and DBA/2J matings revealed a mean of 1.1 ± 0.22 mm 2 , approximately halfway between the means of the parental strains (0.8±0.19 and 1.4±0.27 for C57BL/6J and DBA/2J, respectively; see Fig. 1 ). Phenotyping the BXD strains, which represent a homozygous recombination of the parental strains, resulted in a broad range of values from the BXD-33 value of 0.3 to the BXD-16 value of 2.2. Both are significant deviations from the parental strain values. The mean (and mode) of the vessel areas for the 30 strains was 1.0 ±0.34, slightly, but not significantly, below that of the F1 animals ( Table 1) . As is to be expected with data that is bounded at both the lower and upper end of the range (lower by zero, upper by the fact that the maximal response possible is determined by the growth of vessels completely to the pellet, which is a fixed distance from the limbus), the data are not gaussian but do reasonably approximate a gaussian curve (Fig. 2) . The broad unimodal nature of the RI data distribution combined with the intermediate nature of both the F1 value and the RI mean value suggests the existence of multiple QTLs governing the responsiveness to VEGF.
We have made an effort to ascertain whether environmental variables might alter the responsiveness of these mice to VEGF, because we did note some differences among different eyes within a given strain. To determine sources of variability in the assay, we performed multiple regression using left eye vessel area (to control for environmental contribution), age, C57BL/6J control animal vessel area (to control for differences in pellet batch composition and age), and strain mean (to control for genetic differences) to predict right eye vessel area. Only the genetic contribution to vessel area proved statistically significant in this analysis (P<2×10 −20 ).
Environment effects were near significant but could only explain ~2% of the variance in the data vs. at least 40% explained by genetic factors. We attribute remaining differences to variability in experimental procedure (e.g., exact pellet size and composition, location and size of surgical pocket) or environmentally induced variability not shared by both eyes (e.g., minor abrasion, irritation).
To map the regions of the genome responsible for the genetic variation in VEGF responsiveness, we required the genotypes of the BXD strains at marker positions throughout the genome and the map positions of those markers. Marker genotypes were obtained from two sources. The majority of marker genotypes were obtained from the Mouse Genome Database version 2.8 (MGD) (19) . In addition, selected markers known to be polymorphic between C57BL/6J and DBA/2J mice were genotyped in our laboratory and have been deposited in the MGD. Two marker-map datasets were used in this analysis. The first dataset consisted of all markers typed on any strain with a position on the MGD linkage map (19) together with the position on that map. The second dataset consisted of all markers with annotated positions on the public assemblies of the C57BL/6J mouse genome (21) together with their position on the mouse genome assembly. Analysis with both marker-map position datasets yielded similar results, therefore results using linkage data are presented below unless specific physical locations are mentioned. The data were analyzed using the QTL Cartographer software package (18) .
Single marker analysis yielded significant associations between VEGF-induced vessel area and regions on chromosome 10 centered on D10Mit194 (P<0.01) and D10Mit42 (P<0.01), regions on chromosome 2 centered on D2Mit58 (P<0.03) and D10Mit62 (P<0.03), and a region on chromosome 9 centered on D9Mit359 (P<0.05). In addition, 10 individual markers on chromosomes 1, 2, 4, 5, 7, 11, 12, and 16 showed significant association with VEGF-induced vessel area (Table 2 ) (P<0.05).
SIM (12) (Fig. 3 ) revealed several regions of near significant linkage with the vessel area but no areas of significant linkage. Given the possibility of multiple linked QTL suggested by marker association and the inappropriateness of SIM in such situations (13), we went on to perform CIM (14, 15) (Fig. 3) , with significance levels determined by permutation. This reduced the number of linked areas to two, and these areas exhibited highly significant linkage (P<0.001). We have designated these QTLs as AngVq1 (on chromosome 10) and AngVq2 (on chromosome 2) for angiogenesis due to VEGF.
MIM analysis (16) was then performed (Table 3 ). This revealed several areas linkage, but only regions on chromosome 2 between D2Mit80 and D2Mit82 and on chromosome 10 between D10Mit194 and D10Mit42 were predicted to explain >20% of the variance in the BXD strains. These regions correspond to those predicted in CIM to be linked to VEGF responsiveness, thus confirming this linkage. The additional QTLs predicted by MIM modeling may be the result of the sensitivity of this approach or a result of insufficiently rigorous significance tests; therefore, only regions identified by CIM as significant are named. In addition to location and effect, MIM allows the prediction of epistasis among QTLs in the model. These tests were performed, and no epistatic interactions were revealed. The final model R 2 value was 0.92, indicating that 92% of the variance in the mean VEGF-induced angiogenic response is explicable by the MIMhypothesized QTLs, that is, there is a good fit between the model and the data.
The positions of the QTLs were transferred to a physical map using marker positions annotated in the UCSC (http://genome.ucsc.edu, Feb. 2002 freeze) and the MGSCv3 (21) datasets (see Table 1 ). Because the order of some markers is discordant between the linkage and the sequencing maps, the above analyses were repeated with this dataset. Both marker-map datasets produced linkage to the same areas on chromosomes 2 and 10. MIM with this map also confirmed those areas previously identified. We conclude therefore that there are polymorphisms between C57BL/6J and DBA/2J mice on chromosome 2 between 11.7 and 26.3 Mbp and on chromosome 10 between 46.7 and 82.8 Mbp that modify angiogenic responsiveness to VEGF. Marker genotypes in these regions are in good agreement with this conclusion (Table 1) .
Candidate genes known to be located near the AngVq1 peak include several extracellular matrixassociated components such as proline 4-hydroxylase (P4ha1); several collagens (Col13a1, Col6a1, Col6a2, Col18a1), including the endostatin precursor collagen XVIII (22), a matrix metalloproteinase (Mmp11); and the extracellular matrix receptor component integrin β 2 (Itgb2). All of these may modify endothelial invasion and the associated matrix remodeling during angiogenesis. There are also several angiogenesis-related signaling molecules in the region, including thromboxane A2 receptor (Tbxa2r) (23), ephrin A2 (Efna2) (24) , macrophage migration inhibitory factor (Mif) (25) , and the adenosine A2a receptor (Adora2a), which is associated with angiogenic endothelium (26) .
A few of the candidate genes known to be located in the AngVq2 region that may have a role in VEGF-induced angiogenesis include prostaglandin D2 synthase (Ptgds), which produces precursors to PPAR ligands and is regulated in endothelial cells in response to flow (27) ; a cluster of interleukin 1-related molecules (Il1f9, Il1f10, Il1rn), including interleukin-1 receptor antagonist ,which has been shown to inhibit corneal angiogenesis in rats (28); and endothelial differentiation-related factor 1 (Edf1), a calcium-calmodulin binding transcription factor that may regulate endothelial cell differentiation (29) .
DISCUSSION
These experiments demonstrate that a large fraction of the variance in the mean angiogenic responsiveness among BXD strains of mice can be explained by a few major genetic differences. Because all alleles in RI strains are homozygous, the design of these experiments does not allow for the determination of dominance. Nevertheless, the intermediate nature of the F1 animal mean suggests that the QTLs identified in this report will exhibit additive effects.
In recent years, it has become evident that the host contributes significantly to the progression of a tumor by providing the tumor's blood supply. Recently, genetic alterations in a few angiogenesis genes have been discovered, and these genes may regulate the rate at which tumors develop. An amino acid altering polymorphism in endostatin is associated with a 2.5-fold increased risk of prostate cancer (30) . Furthermore, in individuals with Down's syndrome, the extra copy of the collagen XVIII gene results in elevated endostatin levels, which may account for a decreased prevalence of solid tumors in affected individuals (31) . In addition, alterations in the VEGF promoter and 5′ UTR have been reported that correlate with VEGF production (32) and may affect the development of melanoma (33) . Polymorphisms in several other genes that regulate both angiogenesis and tumor growth have also been shown to affect tumor incidence and growth rates (34) .
The region associated with AngVq2 appears to overlap with several loci whose effects might be explained by alterations in VEGF responsiveness. These include Kwq6 (kidney weight, at chromosome 2 between 11 and 39 cM) (35) , Igf1q1 (Igf1 serum concentration; at chromosome 10, 38 cM) (35) , and the Sluc16 (lung cancer susceptibility, at chromosome 2, 5 cM) (36) . Another lung cancer susceptibility locus, Sluc22, may overlap one of the minor peaks in CIM and correspond to one of the minor MIM identified loci on chromosome 10 (MIM 4, Table 3 ).
The region associated with AngVq1 also overlaps loci whose effects might be explained by alterations in VEGF responsiveness. These include Pas11 (modifier of pulmonary adenoma sensitivity-1 [K-ras] -1; at chromosome 10, 21 cM) (37), Bsc1 (brain size control, at chromosome 10, 40 cM), and Igfbp3q2 (Igfbp3 serum concentration, at chromosome 10, 40 cM) (38) . Igfpb3 is expressed by endothelial cells under conditions expected to induce VEGF and may regulate endothelial cell function (39) .
Also co-located with AngVq1 is Lifespan2, a QTL for overall animal lifespan (40) . In the report identifying this QTL, this genotype was also associated with increased survival in mice that eventually die of cancer (41) . This suggests that multiple late-life diseases, including cancer, may share pathophysiologic mechanisms affected by the same genomic regions (41) . We note that in addition to tumor growth, angiogenesis has been shown to be important in several other pathogenic processes that may affect lifespan, including atherosclerosis and arthritis (42) . Thus, angiogenesis would make a good candidate for the shared pathophysiologic mechanism influencing variation in murine lifespan.
Angiogenesis is involved in several normal and pathogenic processes, including (in addition to those mentioned above) macular degeneration, diabetic retinopathy, psoriasis (42) , endometriosis (43) , wound healing, organ development and regeneration (44) , fat growth (45), hair growth (46), and reproduction (47) . We expect that the genes that regulate angiogenesis will have both prognostic value-(as the relevance of VEGF-responsiveness-modifying polymorphisms in these processes is determined) and therapeutic value (as compounds that modify their activity are identified) in many of these processes.
While the corneal neovascularization assay is indicative of angiogenic response in the eye and may not entirely predict the angiogenic response in other tissues, we believe that most of the polymorphisms that we identified will also regulate angiogenesis systemically. Indeed, a good correlation exists between the corneal angiogenic response and the endothelial migratory ability of cells derived from aortic ring sections of inbred strains, as we reported previously (4). Thus, characterization of novel angiogenesis-regulating genes detected by the QTL mapping of the corneal angiogenic phenotype may broadly identify additional therapeutic targets for antiangiogenic agents. Furthermore, because several drugs currently in development act on the VEGF pathway, an understanding of the genetics of VEGF response may identify loci that predict response to VEGF-directed antiangiogenic therapy. Finally, these experiments reveal the important effect of the host genetics on angiogenesis and therefore on tumor growth and other angiogenesis-associated pathologic processes. The identification of "high angiogenic" individuals who are at risk for diseases dependent on angiogenesis will allow for increased monitoring of disease development and progression, leading to improved prevention and better clinical management. The possibility that specific and novel antiangiogenic therapy can be developed and implemented at early stages of disease development may render affected individuals "low angiogenic" and result in an increase in survival. Table 2 Markers showing significant association with VEGF-induced vessel area a a LR, likelihood ratio; Chr, chromosome; Phy, physical, position on the genome assembly in mega-base pairs; Gen, genetic position on the genetic map in centimorgans; P, likelihood of the hypothesis that the marker is unlinked to VEGF responsiveness; na, not annotated. 
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